RGLS 5040
Alternative Names: RGLS-5040Latest Information Update: 01 Jul 2025
At a glance
- Originator Regulus Therapeutics
- Developer Novartis
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cholestasis